Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison

View Full Paper
Ask AI
Bookmark
Share

Authors

LNLay She Ng

Discussion

Loading...

Member takes

Overview

Retrospective cohort study found zanubrutinib reduced infections and cytopenias compared to acalabrutinib in CLL patients, suggesting a better safety profile.

Key Points

  • The research aims to compare the safety profiles of acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia.
  • Conducted a retrospective cohort study using the TriNetX global health research network.
  • Included patients aged ≥18 years diagnosed with CLL treated with either acalabrutinib or zanubrutinib.
  • Performed propensity score matching based on age, sex, and race.
  • Zanubrutinib showed a statistically significant reduction in fatal hemorrhage, infections, and cytopenias compared to acalabrutinib.
  • Cardiotoxicity events were lower in the zanubrutinib group, including atrial fibrillation and cardiac arrhythmias.
  • No significant differences in hepatic-related adverse events between the two groups.

Cite This Study

Lay She Ng (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbf8https://doi.org/10.1182/blood-2025-7419
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia2026
  2. 2Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort2026 · 4 citations
  3. 3Risk of non-fatal MACE in patients treated with zanubrutinib and acalabrutinib: a propensity-matched analysis2026
  4. 4Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy2025 · 1 citations
  5. 5Cardiotoxicity and safety of zanubrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: a real-world retrospective cohort study using the TriNetX registry2026